Rady Childrens Hospital - San Diego
- Type
- Teaching hospital
- Where
- San Diego, CA
- Medicare CCN
- 053303
- Received
- $188,309 in 84 records, 2020 ($46,857 general, $141,452 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: RADY CHILDRENS HOSPITAL SAN DIEGO Fuzzy (name and state)
- Nonprofit: RADY CHILDRENS HOSPITAL SAN DIEGO Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 14 | $46,857 |
| 2020 | Research payment | 70 | $141,452 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Soleno Therapeutics, Inc. | 2 | $58,794 | 2020 |
| PFIZER INC. | 6 | $57,150 | 2020 |
| Alexion Pharmaceuticals, Inc. | 1 | $20,000 | 2020 |
| DERMIRA, INC. | 1 | $15,250 | 2020 |
| Boehringer Ingelheim Pharma GmbH & Co.KG | 7 | $13,080 | 2020 |
| Nabriva Therapeutics, plc | 5 | $10,465 | 2020 |
| Merck Sharp & Dohme LLC | 28 | $3,591 | 2020 |
| Masimo Corporation | 3 | $3,190 | 2020 |
| Linvatec Corporation | 1 | $2,022 | 2020 |
| Cochlear Americas | 2 | $1,750 | 2020 |
| Phadia US Inc. | 5 | $900 | 2020 |
| Eli Lilly and Company | 2 | $566 | 2020 |
| Incyte Corporation | 16 | $403 | 2020 |
| KARL STORZ Endoscopy-America | 1 | $348 | 2020 |
| Hikma Pharmaceuticals USA | 1 | $318 | 2020 |
| Insulet Corporation | 1 | $300 | 2020 |
| Covidien LP | 1 | $167 | 2020 |
| Vero Biotech Inc. | 1 | $11 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 70 | $141,452 |
| Space rental or facility fees (teaching hospital only) | 4 | $25,250 |
| Consulting Fee | 1 | $15,250 |
| Education | 3 | $3,190 |
| Grant | 2 | $2,190 |
| Gift | 1 | $348 |
| Food and Beverage | 2 | $329 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $300 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Linvatec Corporation | $2,022 | Grant | In-kind items and services | MICROFREE Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-12-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,349 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-12-31 | Masimo Corporation | $897 | Education | In-kind items and services | SedLine Device, Devices | 2020 | |
| 2020-12-31 | Masimo Corporation | $182 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-12-16 | Phadia US Inc. | $150 | Research payment | In-kind items and services | ImmunoCAP Device, Allergy | CABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population | 2020 |
| 2020-12-07 | PFIZER INC. | $13,895 | Research payment | In-kind items and services | ZAVICEFTA NEONATAL SEPSIS TRIAL | 2020 | |
| 2020-11-21 | Masimo Corporation | $2,109 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-11-19 | Vero Biotech Inc. | $11 | Food and Beverage | In-kind items and services | Genosyl Drug, Respiratory Therapy | 2020 | |
| 2020-11-04 | Alexion Pharmaceuticals, Inc. | $20,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-10-16 | Nabriva Therapeutics, plc | $2,275 | Research payment | Cash or cash equivalent | A Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I | 2020 | |
| 2020-09-30 | Soleno Therapeutics, Inc. | $34,894 | Research payment | Cash or cash equivalent | Diazoxide Choline Controlled Release (DCCR) Drug, Prader-Willi Syndrome | A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients w | 2020 |
| 2020-09-30 | Soleno Therapeutics, Inc. | $23,899 | Research payment | Cash or cash equivalent | Diazoxide Choline Controlled Release (DCCR) Drug, Prader-Willi Syndrome | An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with | 2020 |
| 2020-09-24 | Phadia US Inc. | $150 | Research payment | In-kind items and services | ImmunoCAP Device, Allergy | CABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population | 2020 |
| 2020-09-14 | Phadia US Inc. | $300 | Research payment | In-kind items and services | ImmunoCAP Device, Allergy | CABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population | 2020 |
| 2020-09-01 | Phadia US Inc. | $150 | Research payment | In-kind items and services | ImmunoCAP Device, Allergy | CABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population | 2020 |
| 2020-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2,033 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2,033 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,799 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-08-26 | Covidien LP | $167 | Grant | In-kind items and services | Nellcor Device, Pulse Oximetry | 2020 | |
| 2020-08-21 | PFIZER INC. | $2,253 | Research payment | In-kind items and services | ZAVICEFTA NEONATAL SEPSIS TRIAL | 2020 | |
| 2020-08-20 | Phadia US Inc. | $150 | Research payment | In-kind items and services | ImmunoCAP Device, Allergy | CABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $65 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $59 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $49 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $22 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $7 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $5 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-07-02 | Nabriva Therapeutics, plc | $650 | Research payment | Cash or cash equivalent | A Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I | 2020 | |
| 2020-05-29 | Merck Sharp & Dohme LLC | $2,174 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-05-29 | Merck Sharp & Dohme LLC | $458 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-05-29 | Merck Sharp & Dohme LLC | $425 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-05-27 | PFIZER INC. | $14,751 | Research payment | In-kind items and services | XALKORI Drug, ONCOLOGY | FULL A PHASE III STUDY OF 131IMETAIODOBENZYLGUANIDINE 131IMIBG OR CRIZOTINIB FOR TREATMENT OF CHILDREN WITH NEWLY DIAGNO | 2020 |
| 2020-05-27 | PFIZER INC. | $14,751 | Research payment | In-kind items and services | XALKORI Drug, ONCOLOGY | FULL A PHASE III STUDY OF 131IMETAIODOBENZYLGUANIDINE 131IMIBG OR CRIZOTINIB FOR TREATMENT OF CHILDREN WITH NEWLY DIAGNO | 2020 |
| 2020-05-26 | KARL STORZ Endoscopy-America | $348 | Gift | In-kind items and services | FORCEPS GRASPING 4FR 60CM Device, UROLOGY | 2020 | |
| 2020-05-20 | Nabriva Therapeutics, plc | $4,290 | Research payment | Cash or cash equivalent | A Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I | 2020 | |
| 2020-05-08 | Incyte Corporation | $60 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $45 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $45 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $31 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $4 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $3 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-05-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-04-15 | Eli Lilly and Company | $11 | Research payment | In-kind items and services | TRULICITY Drug, Diabetes | A RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACE | 2020 |
| 2020-04-02 | Hikma Pharmaceuticals USA | $318 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-04-01 | PFIZER INC. | $8,000 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | THE UNITED STATES PEDIATRIC MULTICENTER PNEUMOCOCCAL SURVEILLANCE | 2020 |
| 2020-03-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2,033 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-03-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2,033 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-03-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,799 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-03-31 | Nabriva Therapeutics, plc | $650 | Research payment | Cash or cash equivalent | A Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I | 2020 | |
| 2020-03-24 | Merck Sharp & Dohme LLC | $28 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2020 |
| 2020-03-12 | Cochlear Americas | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-03-12 | Cochlear Americas | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-03-09 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-03-09 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-03-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-03-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-03-09 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-03-05 | Insulet Corporation | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2020 | |
| 2020-02-28 | Nabriva Therapeutics, plc | $2,600 | Research payment | Cash or cash equivalent | A Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I | 2020 | |
| 2020-02-27 | PFIZER INC. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EUCRISA Drug, DERMATOLOGY | 2020 | |
| 2020-02-10 | DERMIRA, INC. | $15,250 | Consulting Fee | Cash or cash equivalent | QBREXZA Drug, DERMATOLOGY | 2020 | |
| 2020-01-03 | Eli Lilly and Company | $554 | Research payment | In-kind items and services | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREAT | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Diego, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Diego, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 1,389,526 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 1,386,932 | 3,298,634 | 39,538,223 |
| Median age B01002 | 36.2 | 37.3 | 37.9 |
| Under 18 B01001 | 18.4% | 20.9% | 22.0% |
| 65 and over B01001 | 14.6% | 15.4% | 15.7% |
| Households B11001 | 530,412 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 25.1% | 22.8% | 27.0% |
| Median household income B19013 | $108,077 | $106,268 | $99,122 |
| Median family income B19113 | $128,006 | $122,377 | $113,346 |
| Per capita income B19301 | $57,083 | $51,976 | $49,513 |
| Poverty rate B17001 | 11.0% | 10.3% | 12.0% |
| Unemployment rate B23025 | 6.0% | 6.1% | 6.6% |
| Civilian labor force B23025 | 755,893 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 23.5 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 51.0% | 43.2% | 37.1% |
| Housing units B25001 | 568,668 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 47.3% | 54.6% | 55.9% |
| Renters B25003 | 52.7% | 45.4% | 44.1% |
| Median home value B25077 | $906,700 | $854,700 | $734,700 |
| Median gross rent B25064 | $2,313 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 40.9% | 42.4% | 33.8% |
| Black B03002 | 5.3% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 29.8% | 34.6% | 40.2% |
| Asian B03002 | 17.3% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Diego, CA.
Comments